Abstract
Neuropathy will afflict over half of the approximately 350 million people worldwide who currently suffer from diabetes and around one-third of diabetic patients with neuropathy will suffer from painful symptoms that may be spontaneous or stimulus evoked. Diabetes can be induced in rats or mice by genetic, dietary, or chemical means, and there are a variety of well-characterized models of diabetic neuropathy that replicate either type 1 or type 2 diabetes. Diabetic rodents display aspects of sensorimotor dysfunction such as stimulus-evoked allodynia and hyperalgesia that are widely used to model painful neuropathy. This allows investigation of pathogenic mechanisms and development of potential therapeutic interventions that may alleviate established pain or prevent onset of pain.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Danaei G et al (2011) National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2.7 million participants. Lancet 378(9785):31–40
Nokoff NJ, Rewers M, Cree Green M (2012) The interplay of autoimmunity and insulin resistance in type 1 diabetes. Discov Med 13(69):115–122
Prentki M, Nolan CJ (2006) Islet beta cell failure in type 2 diabetes. J Clin Invest 116(7):1802–1812
Ramlo-Halsted BA, Edelman SV (1999) The natural history of type 2 diabetes. implications for clinical practice. Prim Care 26(4):771–789
Cheng D (2005) Prevalence, predisposition and prevention of type II diabetes. Nutr Metab (Lond) 2:29
Ramarao P, Kaul CL (1999) Insulin resistance: current therapeutic approaches. Drugs Today (Barc) 35(12):895–911
Biessels GJ, Deary IJ, Ryan CM (2008) Cognition and diabetes: a lifespan perspective. Lancet Neurol 7(2):184–190
Thomas PK (1999) Diabetic peripheral neuropathies: their cost to patient and society and the value of knowledge of risk factors for development of interventions. Eur Neurol 41(Suppl 1):35–43
Boulton AJ et al (2005) Diabetic neuropathies: a statement by the American Diabetes Association. Diabetes Care 28(4):956–962
Boulton AJ (2012) Diabetic neuropathy: is pain God’s greatest gift to mankind? Semin Vasc Surg 25(2):61–65
Andersen H (2012) Motor dysfunction in diabetes. Diabetes Metab Res Rev 28(Suppl 1):89–92
Boulton AJ et al (2004) Diabetic somatic neuropathies. Diabetes Care 27(6):1458–1486
Boulton AJ et al (1982) Continuous subcutaneous insulin infusion in the management of painful diabetic neuropathy. Diabetes Care 5(4):386–390
Gibbons CH, Freeman R (2010) Treatment-induced diabetic neuropathy: a reversible painful autonomic neuropathy. Ann Neurol 67(4):534–541
Tavakoli M et al (2010) Corneal confocal microscopy: a novel noninvasive test to diagnose and stratify the severity of human diabetic neuropathy. Diabetes Care 33(8):1792–1797
Behse F, Buchthal F, Carlsen F (1977) Nerve biopsy and conduction studies in diabetic neuropathy. J Neurol Neurosurg Psychiatry 40(11):1072–1082
Brown MJ, Martin JR, Asbury AK (1976) Painful diabetic neuropathy. a morphometric study. Arch Neurol 33(3):164–171
Archer AG et al (1983) The natural history of acute painful neuropathy in diabetes mellitus. J Neurol Neurosurg Psychiatry 46(6):491–499
Kalichman MW, Powell HC, Mizisin AP (1998) Reactive, degenerative, and proliferative Schwann cell responses in experimental galactose and human diabetic neuropathy. Acta Neuropathol 95(1):47–56
Kennedy WR, Wendelschafer-Crabb G, Johnson T (1996) Quantitation of epidermal nerves in diabetic neuropathy. Neurology 47(4):1042–1048
Quattrini C et al (2007) Surrogate markers of small fiber damage in human diabetic neuropathy. Diabetes 56(8):2148–2154
Harris M, Eastman R, Cowie C (1993) Symptoms of sensory neuropathy in adults with NIDDM in the U.S. population. Diabetes Care 16(11):1446–1452
Partanen J et al (1995) Natural history of peripheral neuropathy in patients with non-insulin-dependent diabetes mellitus. N Engl J Med 333(2):89–94
Boulton AJ et al (1985) The prevalence of symptomatic, diabetic neuropathy in an insulin-treated population. Diabetes Care 8(2):125–128
Sorensen L, Molyneaux L, Yue DK (2002) Insensate versus painful diabetic neuropathy: the effects of height, gender, ethnicity and glycaemic control. Diabetes Res Clin Pract 57(1):45–51
Abbott CA et al (2011) Prevalence and characteristics of painful diabetic neuropathy in a large community-based diabetic population in the U.K. Diabetes Care 34(10):2220–2224
Daousi C et al (2004) Chronic painful peripheral neuropathy in an urban community: a controlled comparison of people with and without diabetes. Diabet Med 21(9):976–982
Lustman PJ et al (2000) Depression and poor glycemic control: a meta-analytic review of the literature. Diabetes Care 23(7):934–942
Grandner MA et al (2012) Sleep disturbance is associated with cardiovascular and metabolic disorders. J Sleep Res 21(4):427–433
Tesfaye S et al (1996) Prevalence of diabetic peripheral neuropathy and its relation to glycaemic control and potential risk factors: the EURODIAB IDDM complications study. Diabetologia 39(11):1377–1384
Group D.C.a.C.T.R (1993) The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med 329(14):977–986
Group D.C.a.C.T.R (1995) The effect of intensive diabetes therapy on the development and progression of neuropathy. The Diabetes Control and Complications Trial Research Group. Ann Intern Med 122(8):561–568
Tesfaye S et al (2005) Vascular risk factors and diabetic neuropathy. N Engl J Med 352(4):341–350
Reese NB et al (2006) Restoration of frequency-dependent depression of the H-reflex by passive exercise in spinal rats. Spinal Cord 44(1):28–34
Wiggin TD et al (2009) Elevated triglycerides correlate with progression of diabetic neuropathy. Diabetes 58(7):1634–1640
Tomlinson DR, Gardiner NJ (2008) Glucose neurotoxicity. Nat Rev Neurosci 9(1):36–45
Calcutt NA et al (2009) Therapies for hyperglycaemia-induced diabetic complications: from animal models to clinical trials. Nat Rev Drug Discov 8(5):417–429
Hotta N et al (2012) Long-term clinical effects of epalrestat, an aldose reductase inhibitor, on progression of diabetic neuropathy and other microvascular complications: multivariate epidemiological analysis based on patient background factors and severity of diabetic neuropathy. Diabet Med 29(12):1529–1533
Ziegler D (2011) Current concepts in the management of diabetic polyneuropathy. Curr Diabetes Rev 7(3):208–220
Dyck PJ, Lambert EH, O’Brien PC (1976) Pain in peripheral neuropathy related to rate and kind of fiber degeneration. Neurology 26(5):466–471
Asbury AK, Fields HL (1984) Pain due to peripheral nerve damage: an hypothesis. Neurology 34(12):1587–1590
Britland ST et al (1990) Association of painful and painless diabetic polyneuropathy with different patterns of nerve fiber degeneration and regeneration. Diabetes 39(8):898–908
Llewelyn JG et al (1991) Sural nerve morphometry in diabetic autonomic and painful sensory neuropathy. a clinicopathological study. Brain 114(Pt 2):867–892
McCrimmon RJ, Ryan CM, Frier BM (2012) Diabetes and cognitive dysfunction. Lancet 379(9833):2291–2299
Selvarajah D et al (2011a) Microvascular perfusion abnormalities of the thalamus in painful but not painless diabetic polyneuropathy: a clue to the pathogenesis of pain in type 1 diabetes. Diabetes Care 34(3):718–720
Selvarajah D et al (2008) Thalamic neuronal dysfunction and chronic sensorimotor distal symmetrical polyneuropathy in patients with type 1 diabetes mellitus. Diabetologia 51(11):2088–2092
Sorensen L et al (2008) Differences in metabolites in pain-processing brain regions in patients with diabetes and painful neuropathy. Diabetes Care 31(5):980–981
Selvarajah D et al (2011b) Central nervous system involvement in diabetic neuropathy. Curr Diab Rep 11(4):310–322
Selvarajah D et al (2006) Early involvement of the spinal cord in diabetic peripheral neuropathy. Diabetes Care 29(12):2664–2669
Baron R et al (2009) A cross-sectional cohort survey in 2,100 patients with painful diabetic neuropathy and postherpetic neuralgia: differences in demographic data and sensory symptoms. Pain 146(1–2):34–40
Szkudelski T (2001) The mechanism of alloxan and streptozotocin action in B cells of the rat pancreas. Physiol Res 50(6):537–546
Calcutt NA (2004) Modeling diabetic sensory neuropathy in rats. Methods Mol Med 99:55–65
Freireich EJ et al (1966) Quantitative comparison of toxicity of anticancer agents in mouse, rat, hamster, dog, monkey, and man. Cancer Chemother Rep 50(4):219–244
Kennedy JM, Zochodne DW (2005) Experimental diabetic neuropathy with spontaneous recovery: is there irreparable damage? Diabetes 54(3):830–837
Davidson E et al (2009a) The roles of streptozotocin neurotoxicity and neutral endopeptidase in murine experimental diabetic neuropathy. Exp Diabetes Res 2009:431980
Romanovsky D et al (2006) Mechanical hyperalgesia correlates with insulin deficiency in normoglycemic streptozotocin-treated rats. Neurobiol Dis 24(2):384–394
Willars GB et al (1989) Substance P levels in peripheral nerve, skin, atrial myocardium and gastrointestinal tract of rats with long-term diabetes mellitus. effects of aldose reductase inhibition. J Neurol Sci 91(1–2):153–164
Singhal A et al (1997) Near nerve local insulin prevents conduction slowing in experimental diabetes. Brain Res 763(2):209–214
Hoybergs YM, Meert TF (2007) The effect of low-dose insulin on mechanical sensitivity and allodynia in type I diabetes neuropathy. Neurosci Lett 417(2):149–154
Makino S et al (1980) Breeding of a non-obese, diabetic strain of mice. Jikken Dobutsu 29(1):1–13
Bour-Jordan H et al (2013) Distinct genetic control of autoimmune neuropathy and diabetes in the non-obese diabetic background. J Autoimmun 45:58–67
Izumi T et al (2003) Dominant negative pathogenesis by mutant proinsulin in the Akita diabetic mouse. Diabetes 52(2):409–416
Ron D (2002) Proteotoxicity in the endoplasmic reticulum: lessons from the Akita diabetic mouse. J Clin Invest 109(4):443–445
Choeiri C et al (2005) Longitudinal evaluation of memory performance and peripheral neuropathy in the Ins2C96Y Akita mice. Behav Brain Res 157(1):31–38
Marliss EB et al (1982) The diabetic syndrome of the ‘BB’ Wistar rat: possible relevance to type 1 (insulin-dependent) diabetes in man. Diabetologia 22(4):225–232
Sima AA et al (2000) A comparison of diabetic polyneuropathy in type II diabetic BBZDR/Wor rats and in type I diabetic BB/Wor rats. Diabetologia 43(6):786–793
Kamiya H et al (2005) Unmyelinated fiber sensory neuropathy differs in type 1 and type 2 diabetes. Diabetes Metab Res Rev 21(5):448–458
Rees DA, Alcolado JC (2005) Animal models of diabetes mellitus. Diabet Med 22(4):359–370
Liu YQ, Jetton L, Leahy JL (2002) beta-cell adaptation to insulin resistance. Increased pyruvate carboxylase and malate-pyruvate shuttle activity in islets of nondiabetic zucker fatty rats. J Biol Chem 277(42):39163–39168
Srinivasan K, Ramarao P (2007) Animal models in type 2 diabetes research: an overview. Indian J Med Res 125(3):451–472
Kjorholt C et al (2005) Chronic hyperglycemia, independent of plasma lipid levels, is sufficient for the loss of beta-cell differentiation and secretory function in the db/db mouse model of diabetes. Diabetes 54(9):2755–2763
Pick A et al (1998) Role of apoptosis in failure of beta-cell mass compensation for insulin resistance and beta-cell defects in the male Zucker diabetic fatty rat. Diabetes 47(3):358–364
Seibler J et al (2007) Reversible gene knockdown in mice using a tight, inducible shRNA expression system. Nucleic Acids Res 35(7):e54
Kotnik K et al (2009) Inducible transgenic rat model for diabetes mellitus based on shRNA-mediated gene knockdown. PLoS One 4(4):e5124
Davidson EP et al (2009b) Vascular and neural dysfunctions in obese zucker rats: effect of AVE7688. Exp Diabetes Res 2009:912327
Davidson EP et al (2010) Diet-induced obesity in Sprague-Dawley rats causes microvascular and neural dysfunction. Diabetes Metab Res Rev 26(4):306–318
Vincent AM et al (2009) Dyslipidemia-induced neuropathy in mice: the role of oxLDL/LOX-1. Diabetes 58(10):2376–2385
Zhang M et al (2008) The characterization of high-fat diet and multiple low-dose streptozotocin induced type 2 diabetes rat model. Exp Diabetes Res 2008:704045
Srinivasan K et al (2005) Combination of high-fat diet-fed and low-dose streptozotocin-treated rat: a model for type 2 diabetes and pharmacological screening. Pharmacol Res 52(4):313–320
Airey M et al (2000) Aldose reductase inhibitors for the prevention and treatment of diabetic peripheral neuropathy. Cochrane Database Syst Rev(2):CD002182
Pfeifer MA, Schumer MP (1995) Clinical trials of diabetic neuropathy: past, present, and future. Diabetes 44(12):1355–1361
Carrington AL et al (2002) Can motor nerve conduction velocity predict foot problems in diabetic subjects over a 6-year outcome period? Diabetes Care 25(11):2010–2015
Redmond JM et al (1992) Sensory testing versus nerve conduction velocity in diabetic polyneuropathy. Muscle Nerve 15(12):1334–1339
Morimoto J et al (2012) Time-course changes in nerve conduction velocity (NCV) in type 2 diabetes. J Diabetes Complications 26(3):237–240
Bril V (1994) Role of electrophysiological studies in diabetic neuropathy. Can J Neurol Sci 21(4):S8–S12
Bril V et al (1998) Electrophysiological monitoring in clinical trials. Roche Neuropathy Study Group. Muscle Nerve 21(11):1368–1373
Bril V et al (2009) Ranirestat for the management of diabetic sensorimotor polyneuropathy. Diabetes Care 32(7):1256–1260
Greene DA, De Jesus PV Jr, Winegrad AI (1975) Effects of insulin and dietary myoinositol on impaired peripheral motor nerve conduction velocity in acute streptozotocin diabetes. J Clin Invest 55(6):1326–1336
Ng TF et al (1998) Effects of sorbitol dehydrogenase deficiency on nerve conduction in experimental diabetic mice. Diabetes 47(6):961–966
Sima AA, Robertson DM (1978) The perineurial and blood-nerve barriers in experimental diabetes. Acta Neuropathol 44(3):189–195
Shimoshige Y et al (2000) The effects of zenarestat, an aldose reductase inhibitor, on peripheral neuropathy in zucker diabetic fatty rats. Metabolism 49(11):1395–1399
Britland ST et al (1985) Ultrastructural observations on myelinated fibres in the tibial nerve of streptozotocin-diabetic rats: effect of insulin treatment. Life Support Syst 3(Suppl 1):524–529
Powell H et al (1977) Alloxan diabetic neuropathy: electron microscopic studies. Neurology 27(1):60–66
Tamura E, Parry GJ (1994) Severe radicular pathology in rats with longstanding diabetes. J Neurol Sci 127(1):29–35
Gregory JA et al (2012) Hypertension-induced peripheral neuropathy and the combined effects of hypertension and diabetes on nerve structure and function in rats. Acta Neuropathol 124(4):561–573
Lauria G, Lombardi R (2012) Skin biopsy in painful and immune-mediated neuropathies. J Peripher Nerv Syst 17(Suppl 3):38–45
Lauria G et al (2010) Intraepidermal nerve fiber density at the distal leg: a worldwide normative reference study. J Peripher Nerv Syst 15(3):202–207
Sumner CJ et al (2003) The spectrum of neuropathy in diabetes and impaired glucose tolerance. Neurology 60(1):108–111
Pittenger GL et al (2005) Small fiber neuropathy is associated with the metabolic syndrome. Metab Syndr Relat Disord 3(2):113–121
Smith AG et al (2006) Lifestyle intervention for pre-diabetic neuropathy. Diabetes Care 29(6):1294–1299
Boucek P et al (2008) Epidermal innervation in type 1 diabetic patients: a 2.5-year prospective study after simultaneous pancreas/kidney transplantation. Diabetes Care 31(8):1611–1612
Tavakoli M et al (2013) Corneal confocal microscopy detects early nerve regeneration in diabetic neuropathy after simultaneous pancreas and kidney transplantation. Diabetes 62(1):254–260
Boyd AL et al (2010) Topiramate improves neurovascular function, epidermal nerve fiber morphology, and metabolism in patients with type 2 diabetes mellitus. Diabetes Metab Syndr Obes 3:431–437
Kluding PM et al (2012) The effect of exercise on neuropathic symptoms, nerve function, and cutaneous innervation in people with diabetic peripheral neuropathy. J Diabetes Complications 26(5):424–429
Pittenger GL et al (2004) Intraepidermal nerve fibers are indicators of small-fiber neuropathy in both diabetic and nondiabetic patients. Diabetes Care 27(8):1974–1979
Sorensen L, Molyneaux L, Yue DK (2006) The relationship among pain, sensory loss, and small nerve fibers in diabetes. Diabetes Care 29(4):883–887
Malmberg AB et al (2004) Reduced heat sensitivity and epidermal nerve fiber immunostaining following single applications of a high-concentration capsaicin patch. Pain 111(3):360–367
Beiswenger KK, Calcutt NA, Mizisin AP (2008) Dissociation of thermal hypoalgesia and epidermal denervation in streptozotocin-diabetic mice. Neurosci Lett 442(3):267–272
Bianchi R et al (2004) Erythropoietin both protects from and reverses experimental diabetic neuropathy. Proc Natl Acad Sci U S A 101(3):823–828
Brussee V et al (2008) Distal degenerative sensory neuropathy in a long-term type 2 diabetes rat model. Diabetes 57(6):1664–1673
Underwood RA et al (2001) Color subtractive-computer-assisted image analysis for quantification of cutaneous nerves in a diabetic mouse model. J Histochem Cytochem 49(10):1285–1291
Roy Chowdhury SK et al (2012) Impaired adenosine monophosphate-activated protein kinase signalling in dorsal root ganglia neurons is linked to mitochondrial dysfunction and peripheral neuropathy in diabetes. Brain 135(Pt 6):1751–1766
Diemel LT et al (1994) Expression of neuropeptides in experimental diabetes; effects of treatment with nerve growth factor or brain-derived neurotrophic factor. Brain Res Mol Brain Res 21(1–2):171–175
Tomlinson DR et al (1988) Deficient axonal transport of substance P in streptozocin-induced diabetic rats. effects of sorbinil and insulin. Diabetes 37(4):488–493
Calcutt NA et al (2000a) Elevated substance-P-like immunoreactivity levels in spinal dialysates during the formalin test in normal and diabetic rats. Brain Res 856(1–2):20–27
Tavakoli M et al (2011) Corneal confocal microscopy detects improvement in corneal nerve morphology with an improvement in risk factors for diabetic neuropathy. Diabet Med 28(10):1261–1267
Davidson EP, Coppey LJ, Yorek MA (2012a) Early loss of innervation of cornea epithelium in streptozotocin-induced type 1 diabetic rats: improvement with ilepatril treatment. Invest Ophthalmol Vis Sci 53(13):8067–8074
Davidson EP et al (2012b) Changes in corneal innervation and sensitivity and acetylcholine-mediated vascular relaxation of the posterior ciliary artery in a type 2 diabetic rat. Invest Ophthalmol Vis Sci 53(3):1182–1187
Chen DK et al (2013) Repeated monitoring of corneal nerves by confocal microscopy as a index of peripheral neuropathy in type 1 diabetic rodents and the effects of topical insulin. J Peripheral Nerv Syst (in press)
Vinik A (2005) Clinical review: use of antiepileptic drugs in the treatment of chronic painful diabetic neuropathy. J Clin Endocrinol Metab 90(8):4936–4945
Burchiel KJ et al (1985) Spontaneous activity of primary afferent neurons in diabetic BB/Wistar rats. a possible mechanism of chronic diabetic neuropathic pain. Diabetes 34(11):1210–1213
Khan GM, Chen SR, Pan HL (2002) Role of primary afferent nerves in allodynia caused by diabetic neuropathy in rats. Neuroscience 114(2):291–299
Ahlgren SC, White DM, Levine JD (1992) Increased responsiveness of sensory neurons in the saphenous nerve of the streptozotocin-diabetic rat. J Neurophysiol 68(6):2077–2085
Pertovaara A, Wei H (2001) Peripheral effects of morphine in neuropathic rats: role of sympathetic postganglionic nerve fibers. Eur J Pharmacol 429(1–3):139–145
Russell LC, Burchiel KJ (1993) Abnormal activity in diabetic rat saphenous nerve. Diabetes 42(6):814–819
Fischer TZ, Tan AM, Waxman SG (2009) Thalamic neuron hyperexcitability and enlarged receptive fields in the STZ model of diabetic pain. Brain Res 1268:154–161
Pertovaara A et al (2001) Pain behavior and response properties of spinal dorsal horn neurons following experimental diabetic neuropathy in the rat: modulation by nitecapone, a COMT inhibitor with antioxidant properties. Exp Neurol 167(2):425–434
Silva M et al (2013) Pronociceptive changes in the activity of rostroventromedial medulla (RVM) pain modulatory cells in the streptozotocin-diabetic rat. Brain Res Bull 96:39–44
Jourdan D, Ardid D, Eschalier A (2002) Analysis of ultrasonic vocalisation does not allow chronic pain to be evaluated in rats. Pain 95(1–2):165–173
Courteix C, Eschalier A, Lavarenne J (1993) Streptozocin-induced diabetic rats: behavioural evidence for a model of chronic pain. Pain 53(1):81–88
Wiech K, Tracey I (2009) The influence of negative emotions on pain: behavioral effects and neural mechanisms. NeuroImage 47(3):987–994
Le Bars D, Gozariu M, Cadden SW (2001) Animal models of nociception. Pharmacol Rev 53(4):597–652
Calcutt NA, Freshwater JD, Mizisin AP (2004) Prevention of sensory disorders in diabetic Sprague-Dawley rats by aldose reductase inhibition or treatment with ciliary neurotrophic factor. Diabetologia 47(4):718–724
Calcutt NA et al (1996) Tactile allodynia and formalin hyperalgesia in streptozotocin-diabetic rats: effects of insulin, aldose reductase inhibition and lidocaine. Pain 68(2–3):293–299
Akil H et al (1986) The many possible roles of opioids and related peptides in stress-induced analgesia. Ann N Y Acad Sci 467:140–153
Vidal C, Jacob JJ (1982) Stress hyperalgesia in rats: an experimental animal model of anxiogenic hyperalgesia in human. Life Sci 31(12–13):1241–1244
Haanpaa ML et al (2009) Assessment of neuropathic pain in primary care. Am J Med 122(10 Suppl):S13–S21
Walk D et al (2009) Quantitative sensory testing and mapping: a review of nonautomated quantitative methods for examination of the patient with neuropathic pain. Clin J Pain 25(7):632–640
Chaplan SR et al (1994) Quantitative assessment of tactile allodynia in the rat paw. J Neurosci Methods 53(1):55–63
Mizisin AP et al (1998) Tactile hyperesthesia, altered epidermal innervation and plantar nerve injury in the hindfeet of rats housed on wire grates. Brain Res 788(1–2):13–19
Tavee J, Zhou L (2009) Small fiber neuropathy: a burning problem. Cleve Clin J Med 76(5):297–305
Romanovsky D et al (2004) Relevance of hyperglycemia to early mechanical hyperalgesia in streptozotocin-induced diabetes. J Peripher Nerv Syst 9(2):62–69
Drel VR et al (2007) A peroxynitrite decomposition catalyst counteracts sensory neuropathy in streptozotocin-diabetic mice. Eur J Pharmacol 569(1–2):48–58
Christianson JA et al (2003) Beneficial actions of neurotrophin treatment on diabetes-induced hypoalgesia in mice. J Pain 4(9):493–504
Cheng HT et al (2009) Nerve growth factor mediates mechanical allodynia in a mouse model of type 2 diabetes. J Neuropathol Exp Neurol 68(11):1229–1243
Wright DE et al (2007) Selective changes in nocifensive behavior despite normal cutaneous axon innervation in leptin receptor-null mutant (db/db) mice. J Peripher Nerv Syst 12(4):250–261
Calcutt NA, Freshwater JD, O’Brien JS (2000b) Protection of sensory function and antihyperalgesic properties of a prosaposin-derived peptide in diabetic rats. Anesthesiology 93(5):1271–1278
Backonja M et al (1998) Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus: a randomized controlled trial. JAMA 280(21):1831–1836
Morello CM et al (1999) Randomized double-blind study comparing the efficacy of gabapentin with amitriptyline on diabetic peripheral neuropathy pain. Arch Intern Med 159(16):1931–1937
Ziegler D et al (2006) Oral treatment with alpha-lipoic acid improves symptomatic diabetic polyneuropathy: the SYDNEY 2 trial. Diabetes Care 29(11):2365–2370
Raskin J et al (2005) A double-blind, randomized multicenter trial comparing duloxetine with placebo in the management of diabetic peripheral neuropathic pain. Pain Med 6(5):346–356
Field MJ et al (1999) Gabapentin and pregabalin, but not morphine and amitriptyline, block both static and dynamic components of mechanical allodynia induced by streptozocin in the rat. Pain 80(1–2):391–398
Cameron NE, Jack AM, Cotter MA (2001) Effect of alpha-lipoic acid on vascular responses and nociception in diabetic rats. Free Radic Biol Med 31(1):125–135
Yamamoto H et al (2009) Pharmacological characterization of standard analgesics on mechanical allodynia in streptozotocin-induced diabetic rats. Neuropharmacology 57(4):403–408
Mixcoatl-Zecuatl T, Jolivalt CG (2011) A spinal mechanism of action for duloxetine in a rat model of painful diabetic neuropathy. Br J Pharmacol 164(1):159–169
Obrosova IG (2009) Diabetic painful and insensate neuropathy: pathogenesis and potential treatments. Neurotherapeutics 6(4):638–647
Calcutt NA, Chaplan SR (1997) Spinal pharmacology of tactile allodynia in diabetic rats. Br J Pharmacol 122(7):1478–1482
Tesfaye S et al (2011) Painful diabetic peripheral neuropathy: consensus recommendations on diagnosis, assessment and management. Diabetes Metab Res Rev 27:629–638
Courteix C et al (1994) Study of the sensitivity of the diabetes-induced pain model in rats to a range of analgesics. Pain 57(2):153–160
Ahlgren SC, Levine JD (1993) Mechanical hyperalgesia in streptozotocin-diabetic rats. Neuroscience 52(4):1049–1055
Romanovsky D et al (2010) Comparison of metabolic and neuropathy profiles of rats with streptozotocin-induced overt and moderate insulinopenia. Neuroscience 170(1):337–347
Piercy V et al (1999) Thermal, but not mechanical, nociceptive behavior is altered in the Zucker diabetic fatty rat and is independent of glycemic status. J Diabetes Complications 13(3):163–169
Sugimoto K et al (2008) Time course of pain sensation in rat models of insulin resistance, type 2 diabetes, and exogenous hyperinsulinaemia. Diabetes Metab Res Rev 24(8):642–650
Shun CT et al (2004) Skin denervation in type 2 diabetes: correlations with diabetic duration and functional impairments. Brain 127(Pt 7):1593–1605
Dyck PJ et al (2000) Patterns of quantitative sensation testing of hypoesthesia and hyperalgesia are predictive of diabetic polyneuropathy: a study of three cohorts. Nerve growth factor study group. Diabetes Care 23(4):510–517
Forman LJ et al (1986) Streptozocin diabetes alters immunoreactive beta-endorphin levels and pain perception after 8 week in female rats. Diabetes 35(12):1309–1313
Yeomans DC, Proudfit HK (1994) Characterization of the foot withdrawal response to noxious radiant heat in the rat. Pain 59(1):85–94
Yeomans DC, Proudfit HK (1996) Nociceptive responses to high and low rates of noxious cutaneous heating are mediated by different nociceptors in the rat: electrophysiological evidence. Pain 68(1):141–150
Yeomans DC, Pirec V, Proudfit HK (1996) Nociceptive responses to high and low rates of noxious cutaneous heating are mediated by different nociceptors in the rat: behavioral evidence. Pain 68(1):133–140
Gabra BH et al (2005) Inhibition of type 1 diabetic hyperalgesia in streptozotocin-induced Wistar versus spontaneous gene-prone BB/Worchester rats: efficacy of a selective bradykinin B1 receptor antagonist. J Neuropathol Exp Neurol 64(9):782–789
Stevens MJ et al (2004) C-peptide corrects endoneurial blood flow but not oxidative stress in type 1 BB/Wor rats. Am J Physiol Endocrinol Metab 287(3):E497–E505
Guo G et al (2011) Local insulin and the rapid regrowth of diabetic epidermal axons. Neurobiol Dis 43(2):414–421
Calcutt NA et al (1995) Different effects of two aldose reductase inhibitors on nociception and prostaglandin E. Eur J Pharmacol 285(2):189–197
Puig S, Sorkin LS (1996) Formalin-evoked activity in identified primary afferent fibers: systemic lidocaine suppresses phase-2 activity. Pain 64(2):345–355
Taylor BK, Peterson MA, Basbaum AI (1997) Early nociceptive events influence the temporal profile, but not the magnitude, of the tonic response to subcutaneous formalin: effects with remifentanil. J Pharmacol Exp Ther 280(2):876–883
Malmberg AB, Yaksh TL (1992) Antinociceptive actions of spinal nonsteroidal anti-inflammatory agents on the formalin test in the rat. J Pharmacol Exp Ther 263(1):136–146
Svensson CI, Yaksh TL (2002) The spinal phospholipase-cyclooxygenase-prostanoid cascade in nociceptive processing. Annu Rev Pharmacol Toxicol 42:553–583
Malmberg AB, Yaksh TL, Calcutt NA (1993) Anti-nociceptive effects of the GM1 ganglioside derivative AGF 44 on the formalin test in normal and streptozotocin-diabetic rats. Neurosci Lett 161(1):45–48
Malmberg AB et al (2006) Impaired formalin-evoked changes of spinal amino acid levels in diabetic rats. Brain Res 1115(1):48–53
Freshwater JD et al (2002) Elevated spinal cyclooxygenase and prostaglandin release during hyperalgesia in diabetic rats. Diabetes 51(7):2249–2255
Ramos KM et al (2007) Pathogenesis of spinally mediated hyperalgesia in diabetes. Diabetes 56(6):1569–1576
Jolivalt CG et al (2008) Allodynia and hyperalgesia in diabetic rats are mediated by GABA and depletion of spinal potassium-chloride co-transporters. Pain 140(1):48–57
Lee-Kubli CA, Calcutt NA (2013) Altered rate-dependent depression of the spinal H-reflex as an indicator of spinal disinhibition in models of neuropathic pain. Pain (13)00540-X:S0304–3959
Stucky CL et al (2009) Roles of transient receptor potential channels in pain. Brain Res Rev 60(1):2–23
Eberhardt MJ et al (2012) Methylglyoxal activates nociceptors through transient receptor potential channel A1 (TRPA1): a possible mechanism of metabolic neuropathies. J Biol Chem 287(34):28291–28306
Johnson MS, Ryals JM, Wright DE (2007) Diabetes-induced chemogenic hypoalgesia is paralleled by attenuated stimulus-induced fos expression in the spinal cord of diabetic mice. J Pain 8(8):637–649
Kamei J et al (2000) Modulation of the formalin-induced nociceptive response by diabetes: possible involvement of intracellular calcium. Brain Res 862(1–2):257–261
Ohsawa M, Kashiwazaki T, Kamei J (1998) Modulation of the formalin-induced nociceptive response by diabetes: possible involvement of protein kinase C. Brain Res 803(1–2):198–203
Acknowledgments
Supported by NIH grants DK57629 (NAC) and NIA AG039736 (CGJ), a JDRF Career Development Award (CGJ) and a UC MEXUS-CONACYT Fellowship (TM-Z).
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2014 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Lee-Kubli, C.A., Mixcoatl-Zecuatl, T., Jolivalt, C.G., Calcutt, N.A. (2014). Animal Models of Diabetes-Induced Neuropathic Pain. In: Taylor, B., Finn, D. (eds) Behavioral Neurobiology of Chronic Pain. Current Topics in Behavioral Neurosciences, vol 20. Springer, Berlin, Heidelberg. https://doi.org/10.1007/7854_2014_280
Download citation
DOI: https://doi.org/10.1007/7854_2014_280
Published:
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-662-45093-2
Online ISBN: 978-3-662-45094-9
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)